TY - JOUR
TI - Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group
AU - Moulopoulos, L.A.
AU - Koutoulidis, V.
AU - Hillengass, J.
AU - Zamagni, E.
AU - Aquerreta, J.D.
AU - Roche, C.L.
AU - Lentzsch, S.
AU - Moreau, P.
AU - Cavo, M.
AU - Miguel, J.S.
AU - Dimopoulos, M.A.
AU - Rajkumar, S.V.
AU - Durie, B.G.M.
AU - Terpos, E.
AU - Delorme, S.
JO - Blood cancer journal
PY - 2018
VL - 8
TODO - 10
SP - null
PB - Nature Publishing Group
SN - null
TODO - 10.1038/s41408-018-0124-1
TODO - Article;  bone atrophy;  bone disease;  cancer patient;  compression fracture;  diagnostic imaging;  human;  image analysis;  image quality;  information processing;  low energy radiation;  medical information system;  multiple myeloma;  patient positioning;  peripheral medullary lesion;  plasmacytoma;  radiological parameters;  whole body CT;  aged;  case report;  computer assisted diagnosis;  diagnostic imaging;  female;  image processing;  male;  multiple myeloma;  osteolysis;  pathology;  plasma cell;  procedures;  whole body imaging;  x-ray computed tomography, Aged;  Female;  Humans;  Image Interpretation, Computer-Assisted;  Image Processing, Computer-Assisted;  Male;  Multiple Myeloma;  Osteolysis;  Plasma Cells;  Tomography, X-Ray Computed;  Whole Body Imaging
TODO - Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and has been included in the 2014 International Myeloma Working Group (IMWG) criteria for multiple myeloma (MM) definition. Nevertheless, standardization guidelines for the optimal use of WBLDCT in MM patients are still lacking, preventing its more widespread use, both in daily practice and clinical trials. The aim of this report by the Bone Group of the IMWG is to provide practical recommendations for the acquisition, interpretation and reporting of WBLDCT in patients with multiple myeloma and other plasma cell disorders. © 2018, The Author(s).
ER -